These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 2494640)
1. Long-term tobramycin aerosol therapy in cystic fibrosis. Steinkamp G; Tümmler B; Gappa M; Albus A; Potel J; Döring G; von der Hardt H Pediatr Pulmonol; 1989; 6(2):91-8. PubMed ID: 2494640 [TBL] [Abstract][Full Text] [Related]
2. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Gappa M; Steinkamp G; Tümmler B; von der Hardt H Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515 [TBL] [Abstract][Full Text] [Related]
3. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Smith AL; Ramsey BW; Hedges DL; Hack B; Williams-Warren J; Weber A; Gore EJ; Redding GJ Pediatr Pulmonol; 1989; 7(4):265-71. PubMed ID: 2515523 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683 [TBL] [Abstract][Full Text] [Related]
5. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related]
6. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. MacLusky IB; Gold R; Corey M; Levison H Pediatr Pulmonol; 1989; 7(1):42-8. PubMed ID: 2505216 [TBL] [Abstract][Full Text] [Related]
7. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872 [TBL] [Abstract][Full Text] [Related]
8. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
10. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B; Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612 [TBL] [Abstract][Full Text] [Related]
11. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
12. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
13. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284 [TBL] [Abstract][Full Text] [Related]